A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension
H6D-MC-LVIG - ClinicalTrials.gov - NCT01484431
The purpose of this study to evaluate the drug Tadalafil and how much of the study drug is in the blood after dosing in children with pulmonary arterial hypertension (PAH) and to establish the correct dose for further clinical research.
Trial Summary
Age Range
6 months - 17 yearsConditions the trial is for
Pulmonary Arterial HypertensionWhat the trial is testing?
TadalafilCould I receive a Placebo?
NoEnrollment Goal
20Trial Dates
Jul 17, 2012 - Apr 3, 2019How long will I be in the trial?
Your participation could last approximately 10 weeks with the opportunity to continue taking Tadalafil for at least 2 years.Trial Phase
IILilly Trial Alerts
Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.
You will complete the questionnaire on another website.YesNo